Adalvo successfully launched the first and only Desmopressin Orally Disintegrating Tablets (ODT) in Europe in March 2024.
Developed based on the reference brand Minirin Melt, Desmopressin ODT is indicated for the treatment of diabetes insipidus, primary nocturnal enuresis, and nocturia. Since its launch, Adalvo remains the only company to offer a generic alternative for these treatments.
Adalvo has expanded Desmopressin ODT's availability to over 20 markets through collaborations with more than 10 strategic partnerships. As of today, Adalvo supplies over 30 INNs to more than 150 partners across more than 90 countries globally.
According to IQVIA, Desmopressin ODT reached global sales of $168 million in 2023.
Anil Okay, Adalvo CEO, stated, “The successful launch of Desmopressin ODT in Europe reflects Adalvo's ability to introduce high-quality, differentiated pharmaceutical products to the market. By remaining the only company to offer a generic alternative for these treatments, we continue to reinforce our commitment to our industry partners."
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!